Implandata Ophthalmic Products GmbH says it has successfully carried out a pilot study on the first permanent intraocular pressure sensor implant for glaucoma patients.
The company believes it has demonstrated both the safety and functionality of the implant. What is more, it has collected some important information which will result in new versions of the product and in different implantation procedures. The implant was tested on six patients over a twelve-month period.
The micro-sensor allows the disease's evolution to be followed closely, thus improving the effectiveness of treatments. Being able to obtain intraocular pressure data quickly allows physicians to adjust treatments and, by doing so, to reduce the risk of vision loss. Patients can take the readings themselves in the comfort of their homes and under normal daily living conditions.
This is a major technology milestone and clinical breakthrough, says Professor Robert N. Weinreb, scientific advisor to Implandata. Glaucoma clinicians and researchers from all over the world are eagerly waiting since decades for applicable technologies to continuously measure real intraocular pressure. And apparently this technology is now available.
Source:
